Finger-prick blood self-sampling at home to check cancer drug levels in lung cancer
Tests finger-prick blood self-sampling at home in adults with non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling
Key facts
- Where
- Stockholm, SwedenSee the 2 sites
Where in Sweden
- Institution of Oncology-PathologyStockholm, SwedenNo longer taking part
- Karolinska Univeristy Hospital, Theme Cancer, Lung Cancer DepartmentStockholm, SwedenNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Karolinska Institutet
- Trial code
- NCT07823725
- Record updated
- 21 September 2026
- Original description
This study will evaluate whether people with non-small cell lung cancer (NSCLC) can collect small blood samples themselves using a finger-prick sampling kit. Participants will be receiving standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib.Read full original descriptionShow less
Decentralized Therapeutic Drug Monitoring of Taxanes and ALK Inhibitors in NSCLC: A Real-World Feasibility Study Using the True Dose Capillary Self-Sampling System
This study will evaluate whether people with non-small cell lung cancer (NSCLC) can collect small blood samples themselves using a finger-prick sampling kit. Participants will be receiving standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib.
The blood samples will be used to measure the amount of cancer medicine in the blood. Most samples will be collected by participants at home and returned to a laboratory for analysis. The study will assess how easy the sampling method is to use, whether the collected samples are suitable for laboratory analysis, and how patients and healthcare professionals experience this way of collecting blood samples.
The study will also explore whether measured drug levels are related to side effects, dose changes, treatment delays, or other clinical outcomes. The drug-level results collected in this study will be used for research purposes and will not be used to change participants' cancer treatment.
About 80 participants will take part in the study and will be followed for approximately 3 months.
The microsampling device is CE-marked and used within its approved use exclusively for research and feasibility evaluation. Study results do not influence ongoing clinical treatment decisions.
This study is being conducted as part of Project-COMFORT, a European multi-country initiative aiming to evaluate the feasibility and implementation of PCmS across various populations and healthcare systems.
Inclusion: Age ≥18 years. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC). Receiving ongoing standard-of-care treatment with docetaxel, paclitaxel, alectinib, or lorlatinib; Able to understand Swedish or English and provide written informed consent. Willing and able to comply with study-required procedures, including blood sample collection; Able to perform capillary self-sampling at home, with or without support from a caregiver or healthcare professional; Access to a stable home or remote environment suitable for sample collection and, where applicable, home nurse visits; Able to participate in the required sample collection and shipping procedures, independently or with support from a family member or caregiver.
Exclusion: Concurrent participation in another interventional study that may affect pharmacokinetics; Severe coagulopathy or another contraindication to capillary blood sampling. Known hypersensitivity to a previously used adhesion system used for sample collection; Any condition that, in the investigator's judgment, would make study participation unsafe or infeasible, including skin infection or another skin condition at the intended sample collection site.